KA
ARCT icon

Kovack Advisors’s Arcturus Therapeutics ARCT Stock Holding History

Kovack Advisors’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-46,023
Closed -$282K – 1014
2025
Q4 		$282K Buy
+46,023
New +$497K 0.01% 777

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kovack Advisors's ARCT Position: Q1 2026 in Review

Kovack Advisors sold out of Arcturus Therapeutics (ARCT) in Q1 2026, closing a stake of 46,023 shares — an estimated $282K sold.

Kovack Advisors first reported a position in ARCT in Q4 2025 and held it in 1 quarter. The position peaked at $282K in Q4 2025. 124 funds tracked by Wall St. Rank hold ARCT as of Q1 2026.

  • Kovack Advisors reported no remaining Arcturus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Kovack Advisors sold 46,023 Arcturus Therapeutics shares in Q1 2026, an estimated $282K.
  • Kovack Advisors first reported a position in Arcturus Therapeutics in Q4 2025 and held it in 1 quarter.
  • Kovack Advisors's Arcturus Therapeutics position peaked at $282K in Q4 2025.
  • 124 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2026.

Based on Kovack Advisors's 13F filing for Q1 2026, filed 13 May 2026.